孕11-13周基于母体因素和生物标志物的多中心子痫前期筛查:与NICE指南及ACOG推荐的比较
这项前瞻性多中心研究纳入8775例单胎妊娠,在孕11-13周比较基于母体因素、平均动脉压、子宫动脉搏动指数和血清胎盘生长因子的FMF算法与NICE指南及ACOG推荐的筛查性能。FMF算法在10.0%假阳性率下对孕32周前子痫前期的检出率为100%,对孕37周前为75%,对孕37周及以上为43%,作者认为其远优于NICE和ACOG方法。
要点
- FMF算法联合母体因素、MAP、UtA-PI和PlGF在10.0%假阳性率下检出100%的孕32周前子痫前期。
- NICE指南在10.2%假阳性率下检出41%的孕32周前子痫前期。
- ACOG推荐筛查在64.2%假阳性率下检出94%的孕32周前子痫前期。
核心结论
- 孕11-13周采用FMF算法联合母体因素、MAP、UtA-PI和PlGF筛查子痫前期,性能远优于NICE指南和ACOG推荐的方法。
研究设计与样本
- 前瞻性多中心研究,纳入8775例孕11-13周单胎妊娠,采用已发表的FMF算法计算个体子痫前期风险,并与NICE指南和ACOG推荐比较检出率和假阳性率。
主要发现
- 研究人群中239例(2.7%)发生子痫前期,其中孕32周前17例(0.2%)、孕37周前59例(0.7%)、孕37周及以上180例(2.1%)。
- FMF算法在10.0%假阳性率下检出100%(95%CI 80-100%)的孕32周前子痫前期、75%(95%CI 62-85%)的孕37周前子痫前期和43%(95%CI 35-50%)的孕37周及以上子痫前期。
- NICE指南在10.2%假阳性率下检出41%(95%CI 18-67%)的孕32周前子痫前期、39%(95%CI 27-53%)的孕37周前子痫前期和34%(95%CI 27-41%)的孕37周及以上子痫前期。
- ACOG推荐筛查在64.2%假阳性率下检出94%(95%CI 71-100%)的孕32周前子痫前期、90%(95%CI 79-96%)的孕37周前子痫前期和89%(95%CI 84-94%)的孕37周及以上子痫前期。
- 基于ACOG阿司匹林使用推荐的筛查在0.2%假阳性率下检出6%(95%CI 1-27%)的孕32周前子痫前期、5%(95%CI 2-14%)的孕37周前子痫前期和2%(95%CI 0.3-5%)的孕37周及以上子痫前期。
关键数值与推荐
- NICE指南推荐所有高危妊娠应提供低剂量阿司匹林。
- ACOG推荐阿司匹林应保留用于至少两次前次妊娠有子痫前期病史或前次子痫前期需在孕34周前分娩的妇女。
临床怎么用
- 作者认为孕11-13周采用FMF算法联合母体因素、MAP、UtA-PI和PlGF筛查子痫前期的性能远优于NICE指南和ACOG推荐的方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the performance of screening for pre-eclampsia (PE) based on risk factors from medical history, as recommended by NICE and ACOG, with the method proposed by The Fetal Medicine Foundation (FMF), which uses Bayes' theorem to combine the a-priori risk from maternal factors, derived by a multivariable logistic model, with the results of various combinations of biophysical and biochemical measurements. METHODS: This was a prospective multicenter study of screening for PE in 8775 singleton pregnancies at 11-13 weeks' gestation. A previously published FMF algorithm was used for the calculation of patient-specific risk of PE in each individual. The detection rates (DRs) and false-positive rates (FPRs) for delivery with PE < 32, < 37 and ≥ 37 weeks were estimated and compared with those derived from application of NICE guidelines and ACOG recommendations. According to NICE, all high-risk pregnancies should be offered low-dose aspirin. According to ACOG, use of aspirin should be reserved for women with a history of PE in at least two previous pregnancies or PE requiring delivery < 34 weeks' gestation. RESULTS: In the study population, 239 (2.7%) cases developed PE, of which 17 (0.2%), 59 (0.7%) and 180 (2.1%) developed PE < 32, < 37 and ≥ 37 weeks, respectively. Screening with use of the FMF algorithm based on a combination of maternal factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI) and serum placental growth factor (PlGF) detected 100% (95% CI, 80-100%) of PE < 32 weeks, 75% (95% CI, 62-85%) of PE < 37 weeks and 43% (95% CI, 35-50%) of PE ≥ 37 weeks, at a 10.0% FPR. Screening with use of NICE guidelines detected 41% (95% CI, 18-67%) of PE < 32 weeks, 39% (95% CI, 27-53%) of PE < 37 weeks and 34% (95% CI, 27-41%) of PE ≥ 37 weeks, at 10.2% FPR. Screening with use of ACOG recommendations detected 94% (95% CI, 71-100%) of PE < 32 weeks, 90% (95% CI, 79-96%) of PE < 37 weeks and 89% (95% CI, 84-94%) of PE ≥ 37 weeks, at 64.2% FPR. Screening based on the ACOG recommendations for use of aspirin detected 6% (95% CI, 1-27%) of PE < 32 weeks, 5% (95% CI, 2-14%) of PE < 37 weeks and 2% (95% CI, 0.3-5%) of PE ≥ 37 weeks, at 0.2% FPR. CONCLUSION: Performance of screening for PE at 11-13 weeks' gestation by the FMF algorithm using a combination of maternal factors, MAP, UtA-PI and PlGF, is by far superior to the methods recommended by NICE and ACOG. Copyright © 2017 ISUOG. Published by John Wiley & Sons Ltd.
引用
- O'Gorman N, Wright D, Poon LC, et al. Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison with NICE guidelines and ACOG recommendations. Ultrasound Obstet Gynecol. 2017. PMID: 28295782. doi:10.1002/uog.17455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。